BioAge Labs (NASDAQ:BIOA) Lowered to Sell Rating by Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Monday.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup lifted their price objective on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioAge Labs has a consensus rating of “Hold” and an average price target of $15.00.

BioAge Labs Price Performance

BioAge Labs stock opened at $18.81 on Monday. The firm has a market capitalization of $674.34 million, a P/E ratio of -12.38 and a beta of 1.38. The company’s 50-day moving average is $13.43 and its 200 day moving average is $8.23. BioAge Labs has a 1-year low of $2.88 and a 1-year high of $24.00.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Insider Activity

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. This trade represents a 54.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kristen Fortney sold 233,107 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the completion of the transaction, the chief executive officer owned 976,949 shares in the company, valued at approximately $17,702,315.88. This trade represents a 19.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 347,004 shares of company stock worth $5,673,859 in the last ninety days. Company insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of BioAge Labs during the 3rd quarter valued at approximately $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of BioAge Labs in the 2nd quarter worth approximately $27,000. Nisa Investment Advisors LLC lifted its holdings in shares of BioAge Labs by 4,219.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock worth $135,000 after acquiring an additional 10,000 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after buying an additional 3,517 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.